Atomwise Inc. Overview
Company Headquarters: California, US
Founded: 2012
Workforce: ~ 63
Company Working: Atomwise Inc. (Atomwise) a creative pharmaceutical company, is revolutionizing the search for small-molecule drugs by utilizing AI. The platform for AI-based, structure-based drug development is offered by Atomwise. Deep learning neural networks are used by Atomwise to find new medications. The company achieved the highest outcomes in the world for toxicity detection, binding affinity prediction, and the development of novel pharmacological hits. With three lead-optimization efforts and more than 30 discovery programs, Atomwise is building a wholly owned pipeline of small-molecule pharmaceutical prospects. Additionally, the Bill and Melinda Gates Foundation (US) awarded the company a 2.3 USD million grant in 2020 to support the creation of numerous global health initiatives that will advance cutting-edge antimalarial and anti-tuberculosis small molecule therapies in conjunction with the foundation's extensive network. In addition, Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID-19. The company operates in California US.
Strategy
Atomwise Inc. focuses expertise on the most challenging problems of discovering and developing better drugs and chemicals. It also focused on generating novel small-molecule assets. In addition, the company is focused on expanding its market globally by acquiring small companies and collaborating with major players. furthermore, it is also focusing on the expansion of the company in the new market.
